What is this medicine used for?
FDA-approved uses
- Attention-deficit/hyperactivity disorder (ADHD) — Adults and children aged 6 years and older. This is the Ritalin immediate-release approval; safety and effectiveness below age 6 are not established.Ritalin immediate-release tablets.
- Attention-deficit/hyperactivity disorder (ADHD) — Patients aged 6–65 years. The selected Concerta label does not establish use above age 65 and does not recommend use below age 6.Concerta extended-release tablets.
- Narcolepsy — Patients evaluated for narcolepsy; pediatric safety and effectiveness below age 6 are not established. Narcolepsy is listed in Ritalin labeling; it is not a Concerta indication in the selected label.Ritalin immediate-release tablets.
Read more: ADHD.
What should I expect?
Stimulant effects can occur on the day a dose is taken, while the prescriber evaluates how well the chosen product covers your daily needs. Track attention and function, or wakefulness for narcolepsy, together with appetite, sleep, mood, and pulse or blood-pressure changes.
Agree on a follow-up plan when treatment starts. Contact the prescriber if symptoms worsen, side effects disrupt daily life, or there is no useful improvement by the planned review; do not change the dose yourself.
How do I take it safely?
Take the exact product as prescribed. Ritalin immediate-release tablets are usually taken before meals in divided doses; Concerta is taken each morning with or without food. Swallow Concerta whole—never split, crush, or chew it.
Concerta may be unsuitable with severe bowel narrowing or difficulty swallowing tablets whole. Its empty shell can appear in stool. Do not switch release systems or substitute equal milligram amounts yourself.
Store securely and never share. Review heart history, blood pressure, pulse, appetite, growth in children, sleep, mood, tics, and painful or discolored fingers or toes. Tell the anesthesia team before a procedure.
Allergy to methylphenidate or product ingredients. Current MAOI use or use within 14 days after stopping an MAOI.
The labels advise avoiding use in serious heart disease. Existing glaucoma or raised eye pressure needs an eye-care review and monitoring.
MAO inhibitors can cause a dangerous blood-pressure reaction. Methylphenidate may reduce the effect of blood-pressure medicines. Tell the surgical and anesthesia team about treatment because certain anesthetics interact. Changes in a regimen combining methylphenidate and risperidone may increase movement-related side effects. Review all medicines rather than assuming these examples are a complete interaction list.
The newer Concerta label describes inconsistent pregnancy findings; available evidence does not justify a blanket claim of no risk. Discuss the benefit of treatment, possible fetal risks and untreated ADHD with the care team. Methylphenidate enters breast milk in small amounts in the limited studies; monitor a breastfed infant for agitation, sleep problems, poor feeding or poor weight gain.
Ritalin ADHD approval starts at age 6. Concerta is approved for ages 6–65 and is not recommended below age 6. Growth monitoring remains important throughout pediatric treatment. The selected data do not establish a dosing approach for older adults above the studied age range.
Do not double a dose after forgetting one. A late stimulant dose may impair sleep, so ask the pharmacist for instructions for the exact preparation. Discuss planned pauses or stopping with the prescriber; after prolonged use, abrupt reduction can cause fatigue, depressed mood, appetite change or sleep disturbance. Do not create a personal switch or restart schedule from another formulation’s instructions.
What side effects should I know about?
- Reduced appetite, weight loss, insomnia, headache, anxiety or abdominal discomfort.
- Dry mouth, nausea, sweating, palpitations or increased pulse.
- Concerta is not approved or recommended for children younger than 6. Younger children had higher drug exposure and more adverse effects, including weight loss, than older children at the same dose. The FDA’s June 30, 2025 warning covers extended-release stimulants. Children need height and weight monitoring; report weight loss or slowed growth to the prescriber.
Tell your prescriber about effects that are persistent, troublesome, or interfere with daily life.
Looking for more detailed information?
The official medicine information lists more side effects, safety advice and product instructions.
- View FDA Prescribing Information (PDF) (opens in a new tab)Ritalin immediate-release tablets
- View FDA Prescribing Information (PDF) (opens in a new tab)Concerta extended-release tablets
Which warning signs need help?
- Chest pain, fainting or marked shortness of breath need prompt cardiac assessment.
- Prolonged painful erection, painful eye with visual change, severe allergic reaction or seizures require urgent help.
- New hallucinationsHallucinationsA hallucination is a sensory experience without a corresponding external source—for example, hearing a voice when nobody is speaking. It can involve hearing, sight, touch, smell or taste and may feel very real.A hallucination is an experience; a delusion is a belief. Hallucinations can have different causes, so an assessment is needed to understand them., mania or severe agitation need prompt clinical review; suspected overdose is an emergency.
What else should I know to stay safe?
- Store securely and never share. Do not use after methylphenidate allergy or within 14 days after an MAOI; avoid use in serious heart disease. Monitor pulse, blood pressure, mood, tics, circulation in fingers or toes, and children’s growth. Glaucoma or raised eye pressure needs an eye-care review.
- Concerta must not be crushed, divided, or chewed and may be unsuitable with severe bowel narrowing or inability to swallow it whole. Different release systems cannot be substituted using equal milligram amounts without prescribing advice. Planned stopping or large reductions after prolonged use also need review because withdrawal can occur.
- Methylphenidate can interact with blood-pressure medicines, certain anesthetics, and changes in a risperidone combination. Tell the surgical team before a procedure. Discuss pregnancy and breastfeeding; exposed infants may need monitoring of sleep, feeding, and weight. Concerta’s approval is for ages 6–65; other products have their own scope.
Urgent help and crisis support · Emergency & Crisis Resources (US)
What can help day to day?
- An empty Concerta shell can appear in stool after the medicine has been released. This is expected and does not usually mean the dose was lost.
- Two methylphenidate products can contain the same ingredient but release it differently. A product change needs clear instructions from the prescriber or pharmacist.
How does it work?
Methylphenidate changes the handling of dopamine and norepinephrine, chemical messengers used by nerve cells. It reduces their return into cells, allowing more to remain available between them. This action is well described, although the complete explanation of how it improves attention-deficit/hyperactivity disorder (ADHD) symptoms remains uncertain.
Explore more in Brain & Science: Stimulant Transport: Methylphenidate.
How was this medicine developed?
Ritalin received U.S. approval in 1955. Concerta was approved in 2000, using an extended-release tablet to deliver methylphenidate differently through the day. The release system remains part of the prescription, not simply a change of brand name.
How do I say the name?
Methylphenidate: meth-il-FEN-ih-dayt. Capital letters show the stressed syllable.
Medicine forms and official information
Match the full name, release type and route on your prescription. Different formulations need their own prescribing instructions; do not switch or substitute them yourself.
Choose a formulation
Metadate ER
Methylphenidate extended-release tablets
This is the Metadate ER label record. It does not establish current brand availability; Concerta instructions do not apply to this product.
Official product information: Metadate ER — U.S. official label (DailyMed)
Metadate CD
Methylphenidate extended-release capsules
This capsule product has its own label; it is not the Metadate ER tablet.
Official product information: Metadate CD — U.S. official label (DailyMed)
Ritalin immediate-release tablets
Immediate-release and extended-release products have different dosing, delivery, ages and indications; no direct substitution.
Concerta extended-release tablets
Immediate-release and extended-release products have different dosing, delivery, ages and indications; no direct substitution.
Sources and References
Sources support the U.S. products described here. Product instructions can differ; use the information supplied with your own medicine.
- Ritalin: FDA prescribing information, February 2025
- Concerta: FDA prescribing information, April 2026
- Methylphenidate: patient information
- Ritalin: FDA approval and product record
- Concerta: FDA approval and product record
- Concerta extended-release tablets: current prescribing information
- FDA requires expanded labeling about weight loss risk in patients younger than 6 years taking extended-release stimulants for ADHD
- Ritalin (methylphenidate): prescribing information — mechanism explanation
Scope: Mechanism explanation only. Source sections checked: 12.1 Mechanism of Action; 12.2 Pharmacodynamics; 12.3 Pharmacokinetics..
- Concerta: Package Insert / Prescribing Information / MOA
- ISMP List of Confused Drug Names
- Schizophrenia
- NIMH: Understanding psychosis
- DailyMed - METADATE ER- methylphenidate hydrochloride tablet, extended release
- DailyMed - METADATE CD- methylphenidate hydrochloride capsule, extended release
Giving medicine safely to children: family guide (PDF, 3 pages)

